Search

Your search keyword '"Yeh, Ming-Lun"' showing total 652 results
Start Over Author "Yeh, Ming-Lun" Language english
652 results on '"Yeh, Ming-Lun"'

1. Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan

Author

Chang, Chin-Wei, Hsu, Wei-Fan, Tseng, Kuo-Chih, Chen, Chi-Yi, Cheng, Pin-Nan, Hung, Chao-Hung, Lo, Ching-Chu, Bair, Ming-Jong, Chen, Chien-Hung, Lee, Pei-Lun, Lin, Chun-Yen, Kuo, Hsing-Tao, Chen, Chun-Ting, Yang, Chi-Chieh, Huang, Jee-Fu, Tai, Chi-Ming, Hu, Jui-Ting, Lin, Chih-Lang, Su, Wei-Wen, Tsai, Wei-Lun, Huang, Yi-Hsiang, Cheng, Chien-Yu, Lin, Chih-Lin, Wang, Chia-Chi, Yang, Sheng-Shun, Mo, Lein-Ray, Chen, Guei-Ying, Chang, Chun-Chao, Wang, Szu-Jen, Huang, Chia-Sheng, Hsieh, Tsai-Yuan, Lin, Chih-Wen, Lee, Tzong-Hsi, Chong, Lee-Won, Huang, Chien-Wei, Chang, Shiuh-Nan, Tsai, Ming-Chang, Hsu, Shih-Jer, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Lin, Han-Chieh, Tsai, Pei-Chien, Yeh, Ming-Lun, Huang, Chung-Feng, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Peng, Cheng-Yuan

Published
2024
Full Text
View/download PDF

2. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan

Author

Yang, Chun-Chi, Huang, Chung-Feng, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Kuo, Hsing-Tao, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Tseng, Kuo-Chih, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2024
Full Text
View/download PDF

3. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan

Author

Yu, Ming-Lung, Tai, Chi‐Ming, Mo, Lein-Ray, Kuo, Hsing-Tao, Huang, Chung-Feng, Tseng, Kuo-Chih, Lo, Ching-Chu, Bair, Ming-Jong, Wang, Szu-Jen, Huang, Jee-Fu, Yeh, Ming-Lun, Chen, Chun-Ting, Tsai, Ming-Chang, Huang, Chien-Wei, Lee, Pei-Lun, Yang, Tzeng-Hue, Huang, Yi-Hsiang, Chong, Lee-Won, Chen, Chien-Lin, Yang, Chi-Chieh, Hung, Chao-Hung, Yang, Sheng‐Shun, Cheng, Pin-Nan, Hsieh, Tsai-Yuan, Hu, Jui-Ting, Wu, Wen-Chih, Cheng, Chien-Yu, Chen, Guei-Ying, Zhou, Guo-Xiong, Tsai, Wei-Lun, Kao, Chien-Neng, Lin, Chih-Lang, Wang, Chia-Chi, Lin, Ta-Ya, Lin, Chih‐Lin, Su, Wei-Wen, Lee, Tzong-Hsi, Chang, Te-Sheng, Liu, Chun-Jen, Dai, Chia-Yen, Chen, Chi-Yi, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wan-Long, and Peng, Cheng-Yuan

Published
2024
Full Text
View/download PDF

4. An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection

Author

Mukherji, Atish, Jühling, Frank, Simanjuntak, Yogy, Crouchet, Emilie, Del Zompo, Fabio, Teraoka, Yuji, Haller, Alexandre, Baltzinger, Philippe, Paritala, Soumith, Rasha, Fahmida, Fujiwara, Naoto, Gadenne, Cloé, Slovic, Nevena, Oudot, Marine A., Durand, Sarah C., Ponsolles, Clara, Schuster, Catherine, Zhuang, Xiaodong, Holmes, Jacinta, Yeh, Ming-Lun, Abe-Chayama, Hiromi, Heikenwälder, Mathias, Sangiovanni, Angelo, Iavarone, Massimo, Colombo, Massimo, Foung, Steven K. H., McKeating, Jane A., Davidson, Irwin, Yu, Ming-Lung, Chung, Raymond T., Hoshida, Yujin, Chayama, Kazuaki, Lupberger, Joachim, and Baumert, Thomas F.

Published
2024
Full Text
View/download PDF

5. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study

Author

Shih, Chin-I., Wu, Kuan-Ta, Hsieh, Meng-Hsuan, Yang, Jeng-Fu, Chen, Yi-Yu, Tsai, Wei-Lun, Chen, Wen-Chi, Liang, Po-Cheng, Wei, Yu-Ju, Tsai, Pei-Chien, Hsu, Po-Yao, Hsieh, Ming-Yen, Lin, Yi-Hung, Jang, Tyng-Yuan, Wang, Chih-Wen, Yeh, Ming-Lun, Huang, Chung-Feng, Huang, Jee-Fu, Dai, Chia-Yen, Ho, Chi-Kung, Chuang, Wan-Long, and Yu, Ming-Lung

Published
2024
Full Text
View/download PDF

6. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study

Author

Wong, Yu Jun, Tran, Sally, Huang, Chung-Feng, Hsu, Yao-Chun, Preda, Carmen, Toyoda, Hidenori, Liu, Joanne, Jun, Dae Won, Landis, Charles, Huang, Daniel Q., Gila, Andrei, Negoita, Livia, Yasuda, Satoshi, Tseng, Cheng-Hao, Tsai, Pei-Chien, Uojima, Haruki, Nozaki, Akito, Chuma, Makoto, Atsukawa, Masanori, Ishigami, Masatoshi, Itokawa, Norio, Iio, Etsuko, Lam, Carla Pui-Mei, Watanabe, Tsunamasa, Asai, Akira, Yokohama, Keisuke, Abe, Hiroshi, Enomoto, Masaru, Kawada, Norifumi, Tamori, Akihiro, Lee, Dong Hyun, Jun, Mi Jung, Do, Son, Vo, Dang K. H., Liu, Li, Li, Junyi, Ji, Fanpu, Wang, Wenjun, Li, Yu, Wang, Xiaozhong, Guo, Fen, Xu, Qiang, Jing, Liang, Ye, Qing, Pan, Hongying, Zhang, JiaJie, Wen, Xie, Wang, Qi, Ren, Hong, Cai, Dachuan, Shang, Jia, Liu, Junping, Lu, Chengzheng, Zang, Wenqian, Li, Jia, Niu, Junqi, Zhang, Mingyuan, Wu, Chao, Huang, Rui, Maeda, Mayumi, Nakanishi, Akiko, Yeh, Ming-Lun, Chuang, Wan-Long, Huang, Jee-Fu, Dai, ChiaYen, Ishikawa, Toru, Takaguchi, Koichi, Senoh, Tomonori, Trinh, Huy N., Takahashi, Hirokazu, Eguchi, Yuichiro, Quek, Sabrina Xin Zi, Haga, Hiroaki, Ogawa, Eiichi, Wong, Grace, Buti, Maria, Fukunishi, Shinya, Ueno, Yoshiyuki, Yuen, Man-Fung, Tanaka, Yasuhito, Lim, Seng Gee, Cheung, Ramsey, Yu, Ming-Lung, and Nguyen, Mindie H.

Published
2023
Full Text
View/download PDF

8. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world

Author

Kudaravalli, Sahith, Huang, Daniel Q., Yeh, Ming-Lun, Trinh, Lindsey, Tsai, P.C., Hsu, Yao-Chun, Kam, Leslie Y., Nguyen, Vy H., Ogawa, Eiichi, Lee, Dong Hyun, Ito, Takanori, Watanabe, Tsunamasa, Enomoto, Masaru, Preda, Carmen Monica, Ko, Michael K.L., Wan-Hin Hui, Rex, Atsukawa, Masanori, Suzuki, Takanori, Marciano, Sebastian, Barreira, Ana, Do, Son, Uojima, Haruki, Takahashi, Hirokazu, Quek, Sabrina X.Z., Toe Wai Khine, Htet Htet, Ishigami, Masatoshi, Itokawa, Norio, Go, Min Seok, Kozuka, Ritsuzo, Marin, Raluca Ioana, Sandra, Irina, Li, Jiayi, Zhang, Jian Q., Wong, Christopher, Yoshimaru, Yoko, Vo, Dang K.H., Tseng, Cheng-Hao, Lee, Chul-jin, Inoue, Kaori, Maeda, Mayumi, Hoang, Joseph K., Chau, Angela, Chuang, Wan-Long, Dai, Chia-Yen, Huang, Jee-Fu, Huang, Chung-Feng, Buti, Maria, Tanaka, Yasuhito, Gadano, Adrian Carlos, Yuen, Man-Fung, Cheung, Ramsey, Lim, Seng Gee, Trinh, Huy N., Toyoda, Hidenori, Yu, Ming-Lung, and Nguyen, Mindie H.

Published
2024
Full Text
View/download PDF

10. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry

Author

Chang, Te-Sheng, Huang, Chung-Feng, Kuo, Hsing-Tao, Lo, Ching-Chu, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Chen, Chi-Yi, Tseng, Kuo-Chih, Hung, Chao-Hung, and Yu, Ming-Lung

Published
2023
Full Text
View/download PDF

11. Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study

Author

Chau, Angela, Yeh, Ming-Lun, Tsai, Pei-Chien, Huang, Daniel Q., Kim, Sung Eun, Trinh, Huy, Yoon, Eileen L., Oh, Hyunwoo, Jeong, Jae Yoon, Ahn, Sang Bong, An, Jihyun, Tseng, Cheng-Hao, Hsu, Yao-Chun, Jeong, Soung Won, Cho, Yong Kyun, Shim, Jae-Jun, Kim, Hyoung Su, Ito, Takanori, Marciano, Sebastián, Kawashima, Keigo, Suzuki, Takanori, Watanabe, Tsunamasa, Nozaki, Akito, Ishikawa, Toru, Inoue, Kaori, Eguchi, Yuichiro, Uojima, Haruki, Abe, Hiroshi, Takahashi, Hirokazu, Chuma, Makoto, Ishigami, Masatoshi, Hoang, Joseph K., Maeda, Mayumi, Huang, Chung-Feng, Gadano, Adrian, Dai, Chia-Yen, Huang, Jee-Fu, Tanaka, Yasuhito, Chuang, Wan-Long, Lim, Seng Gee, Cheung, Ramsey, Yu, Ming-Lung, Jun, Dae-Won, and Nguyen, Mindie H.

Published
2024
Full Text
View/download PDF

13. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort

Author

Hsu, Yao-Chun, Jun, Dae Won, Peng, Cheng-Yuan, Yeh, Ming-Lun, Trinh, Huy, Wong, Grace Lai-Hung, Kim, Sung Eun, Chen, Chien-Hung, Oh, Hyunwoo, Lin, Chia-Hsin, Trinh, Lindsey, Wong, Vincent Wai-Sun, Yoon, Eilleen, Ahn, Sang Bong, Huang, Daniel, Cho, Yong Kyun, Jeong, Jae Yoon, Jeong, Soung Won, Kim, Hyoung Su, Xie, Qing, Liu, Li, Riveiro-Barciela, Mar, Tsai, Pei-Chien, Accarino, Elena Vargas, Toyoda, Hidenori, Enomoto, Masaru, Preda, Carmen, Marciano, Sebastián, Hoang, Joseph, Huang, Chung-Feng, Kozuka, Ritsuzo, Yasuda, Satoshi, Istratescu, Doina, Lee, Dong-Hyun, Su, Jia-Ying, Huang, Yen-Tsung, Huang, Jee Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yuen, Man-Fung, Gadano, Adrian, Cheung, Ramsey, Lim, Seng Gee, Buti, Maria, Yu, Ming-Lung, and Nguyen, Mindie H.

Published
2022
Full Text
View/download PDF

17. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan

Author

Tsai, Pei-Chien, Kuo, Hsing-Tao, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Peng, Cheng-Yuan, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Lin, Chun-Yen, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Tung, Shui-Yi, Tai, Chi-Ming, Lin, Chih-Wen, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Yeh, Ming-Lun, Huang, Chung-Feng, Hsieh, Meng-Hsuan, Huang, Jee-Fu, Dai, Chia-Yen, Chung, Wan-Long, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2023
Full Text
View/download PDF

19. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan

Author

Lo, Ching-Chu, Huang, Chung-Feng, Cheng, Pin-Nan, Tseng, Kuo-Chih, Chen, Chi-Yi, Kuo, Hsing-Tao, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Chen, Chien-Hung, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, Chang, Te Sheng, Huang, Jee-Fu, Yang, Chi-Chieh, Hu, Jui-Ting, Lin, Chih-Wen, Chen, Chun-Ting, Wang, Chia-Chi, Su, Wei-Wen, Hsieh, Tsai-Yuan, Lin, Chih-Lin, Tsai, Wei-Lun, Lee, Tzong-Hsi, Chen, Guei-Ying, Wang, Szu-Jen, Chang, Chun-Chao, Mo, Lein-Ray, Yang, Sheng-Shun, Wu, Wen-Chih, Huang, Chia-Sheng, Hsiung, Chou-Kwok, Kao, Chien-Neng, Tsai, Pei-Chien, Liu, Chen-Hua, Lee, Mei-Hsuan, Liu, Chun-Jen, Dai, Chia-Yen, Chuang, Wan-Long, Lin, Han-Chieh, Kao, Jia-Horng, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

21. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)

Author

Huang, Chung-Feng, Tseng, Kuo-Chih, Cheng, Pin-Nan, Hung, Chao-Hung, Lo, Ching-Chu, Peng, Cheng-Yuan, Bair, Ming-Jong, Yeh, Ming-Lun, Chen, Chien-Hung, Lee, Pei-Lun, Lin, Chun-Yen, Kuo, Hsing-Tao, Chen, Chun-Ting, Yang, Chi-Chieh, Huang, Jee-Fu, Tai, Chi-Ming, Hu, Jui-Ting, Lin, Chih-Lang, Su, Wei-Wen, Tsai, Wei-Lun, Huang, Yi-Hsiang, Cheng, Chien-Yu, Lin, Chih-Lin, Wang, Chia-Chi, Yang, Sheng-Shun, Mo, Lein-Ray, Chen, Guei-Ying, Chang, Chun-Chao, Wang, Szu-Jen, Huang, Chia-Sheng, Hsieh, Tsai-Yuan, Lin, Chih-Wen, Lee, Tzong-Hsi, Chong, Lee-Won, Huang, Chien-Wei, Chang, Shiuh-Nan, Tsai, Ming-Chang, Hsu, Shih-Jer, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Lin, Han-Chieh, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Chuang, Wan-Long, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

22. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine

Author

Park, Jiyoon, Le, An K., Tseng, Tai-Chung, Yeh, Ming-Lun, Jun, Dae Won, Trinh, Huy, Wong, Grace L.H., Chen, Chien-Hung, Peng, Cheng-Yuan, Kim, Sung Eun, Oh, Hyunwoo, Kwak, Min-Sun, Cheung, Ka Shing, Toyoda, Hidenori, Hsu, Yao-Chun, Jeong, Jae Yoon, Yoon, Eileen L., Ungtrakul, Teerapat, Zhang, Jian, Xie, Qing, Ahn, Sang Bong, Enomoto, Masaru, Shim, Jae-Jun, Cunningham, Chris, Jeong, Soung Won, Cho, Yong Kyun, Ogawa, Eiichi, Huang, Rui, Lee, Dong-Hyun, Takahashi, Hirokazu, Tsai, Pei-Chien, Huang, Chung-Feng, Dai, Chia-Yen, Tseng, Cheng-Hao, Yasuda, Satoshi, Kozuka, Ritsuzo, Li, Jiayi, Wong, Christopher, Wong, Clifford C., Zhao, Changqing, Hoang, Joseph, Eguchi, Yuichiro, Wu, Chao, Tanaka, Yasuhito, Gane, Ed, Tanwandee, Tawesak, Cheung, Ramsey, Yuen, Man-Fung, Lee, Hyo-Suk, Yu, Ming-Lung, Kao, Jia-Horng, Yang, Hwai-I, and Nguyen, Mindie H.

Published
2022
Full Text
View/download PDF

23. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan

Author

Cheng, Pin-Nan, Mo, Lein-Ray, Chen, Chun-Ting, Chen, Chi-Yi, Huang, Chung-Feng, Kuo, Hsing-Tao, Lo, Ching-Chu, Tseng, Kuo-Chih, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Chen, Chien-Hung, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, Chang, Te Sheng, Huang, Jee-Fu, Yang, Chi-Chieh, Hu, Jui-Ting, Lin, Chih-Wen, Wang, Chia-Chi, Su, Wei-Wen, Hsieh, Tsai-Yuan, Lin, Chih-Lin, Tsai, Wei-Lun, Lee, Tzong-Hsi, Chen, Guei-Ying, Wang, Szu-Jen, Chang, Chun-Chao, Yang, Sheng-Shun, Wu, Wen-Chih, Huang, Chia-Sheng, Chou, Kwok-Hsiung, Kao, Chien-Neng, Tsai, Pei-Chien, Liu, Chen-Hua, Lee, Mei-Hsuan, Cheng, Chien-Yu, Tsai, Ming-Chang, Liu, Chun-Jen, Dai, Chia-Yen, Lin, Han-Chieh, Kao, Jia-Horng, Chuang, Wan-Long, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

24. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study

Author

Mak, Lung-Yi, Hoang, Joseph, Jun, Dae Won, Chen, Chien-Hung, Peng, Cheng-Yuan, Yeh, Ming-Lun, Kim, Sung Eun, Huang, Daniel Q., Jeong, Jae Yoon, Yoon, Eileen, Oh, Hyunwoo, Tsai, Pei-Chien, Huang, Chung-Feng, Ahn, Sang Bong, Trinh, Huy, Xie, Qing, Wong, Grace L. H., Enomoto, Masaru, Shim, Jae-Jun, Lee, Dong-Hyun, Liu, Li, Kozuka, Ritsuzo, Cho, Yong Kyun, Jeong, Soung Won, Kim, Hyoung Su, Trinh, Lindsey, Dao, Allen, Huang, Rui, Hui, Rex Wan-Hin, Tsui, Vivien, Quek, Sabrina, Khine, Htet Htet toe Wai, Ogawa, Eiichi, Dai, Chia Yen, Huang, Jee Fu, Cheung, Ramsey, Wu, Chao, Chuang, Wan-Long, Lim, Seng Gee, Yu, Ming-Lung, Yuen, Man-Fung, and Nguyen, Mindie H.

Published
2022
Full Text
View/download PDF

27. Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist.

Author

Yeh, Ming-Lun, Huang, Jee-Fu, Dai, Chia-Yen, Huang, Chung-Feng, Yu, Ming-Lung, and Chuang, Wan-Long

Subjects
TYPE 2 diabetes, HEPATIC fibrosis, INSULIN resistance, YOUNG adults, LIVER diseases
Abstract

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (DM) are the most prevalent metabolic disorders globally. The numbers affected in both disorders are also rapidly increasing with alarming trends in children and young adults. Areas covered: Insulin resistance (IR) and the subsequent metabolic dysregulation are the fundamental pathogenesis pathways of the prevalent metabolic disorders. The interaction and impacts are bidirectional between MASLD and DM in terms of disease mechanisms, disease course, risks, and prognosis. There's a pressing issue for highlighting the links between MASLD and DM for both care specialists and primary care providers. The review collected the scientific evidence addressing the mutual interactions between the two disorders. The strategies for surveillance, risk stratification, and management are discussed in a practical manner. It also provides individualized viewpoints of patient care in hepatology and diabetology. Expert opinion: Both MASLD and DM shared similar disease mechanisms, and affected the disease development and progression in a bidirectional manner. The high prevalence and the cross-link between the two disorders raise clinical issues from awareness, screening, risk stratification, optimal referral, to appropriate management for primary care providers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.

Author

Tsai, Pei-Chien, Huang, Chung-Feng, Yeh, Ming-Lun, Hsieh, Meng-Hsuan, Kuo, Hsing-Tao, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Peng, Cheng-Yuan, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, and Lin, Chun-Yen

Published
2024
Full Text
View/download PDF

30. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Author

Yeh, Ming-Lun, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Chen, Chi-Yi, Kuo, Hsing-Tao, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Tai, Chi‐Ming, Lin, Chih-Wen, Kao, Jia-Horng, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Lin, Chun-Yen, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Tung, Shui-Yi, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Huang, Chung-Feng, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Tsai, Pei-Chien, Peng, Cheng-Yuan, Liu, Chun-Jen, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

32. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients

Author

Liu, Matt, Tseng, Tai-Chung, Jun, Dae Won, Yeh, Ming-Lun, Trinh, Huy, Wong, Grace L. H., Chen, Chien-Hung, Peng, Cheng-Yuan, Kim, Sung Eun, Oh, Hyunwoo, Kwak, Min-Sun, Cheung, Michael, Toyoda, Hidenori, Hsu, Yao-Chun, Jeong, Jae Yoon, Yoon, Eileen L., Ungtrakul, Teerapat, Zhang, Jian, Xie, Qing, Ahn, Sang Bong, Enomoto, Masaru, Shim, Jae-Jun, Cunningham, Chris, Jeong, Soung Won, Cho, Yong Kyun, Ogawa, Eiichi, Huang, Rui, Lee, Dong-Hyun, Takahashi, Hirokazu, Tsai, Pei-Chien, Huang, Chung-Feng, Dai, Chia-Yen, Tseng, Cheng-Hao, Yasuda, Satoshi, Kozuka, Ritsuzo, Li, Jiayi, Wong, Christopher, Wong, Clifford C., Zhao, Changqing, Hoang, Joseph, Eguchi, Yuichiro, Wu, Chao, Tanaka, Yasuhito, Gane, Ed, Tanwandee, Tawesak, Cheung, Ramsey, Yuen, Man-Fung, Lee, Hyo-Suk, Yu, Ming-Lung, Kao, Jia-Horng, Yang, Hwai-I., and Nguyen, Mindie H.

Published
2021
Full Text
View/download PDF

33. The efficacy of multi‐disciplinary lifestyle modifications in Taiwanese nonalcoholic steatohepatitis patients.

Author

Yeh, Ming‐Lun, Dai, Chia‐Yen, Huang, Chung‐Feng, Huang, Shiu‐Feng, Tsai, Pei‐Chien, Hsu, Po‐Yau, Huang, Ching‐I, Wei, Yu‐Ju, Liang, Po‐Cheng, Bair, Ming‐Jong, Lee, Mei‐Hsuan, Lin, Zu‐Yau, Huang, Jee‐Fu, Yu, Ming‐Lung, and Chuang, Wan‐Long

Subjects
NON-alcoholic fatty liver disease, WEIGHT loss, FATTY liver, BLOOD sugar
Abstract

Lifestyle modification is the standard of care for nonalcoholic fatty liver disease (NAFLD) patients. We aimed to investigate the efficacy of a short‐term lifestyle modification program in the disease course of Taiwanese nonalcoholic steatohepatitis (NASH) patients with paired biopsies. All patients received a 6‐month, strict multidisciplinary program of lifestyle modifications led by physicians, dieticians, and nursing staff. The histopathological and clinical features were assessed. The endpoints were normalization of transaminase levels, metabolic parameters, a decrease in the NAFLD activity score (NAS) ≥1, and a decrease in the fibrosis stage ≥1. We also aimed to elucidate the predictors associated with disease progression. A total of 37 patients with biopsy‐proven NASH were enrolled. The normalization of transaminase levels increased from 0% to 13.5%. There were also significantly increased proportions of patients with normal total cholesterol, triglyceride, and hemoglobin A1c levels. Fifteen (40.5%) patients had an increased NAS ≥1, whereas 10 (27.0%) patients had NAS regression. Twelve (32.4%) patients had increased fibrosis ≥1 stage. Only 2 (5.4%) patients experienced fibrosis regression. A high fasting plasma glucose (FPG) level was associated with NAS progression. Older age and higher transaminase and FPG levels were factors associated with fibrosis progression. Seven (18.9%) patients achieved a body weight reduction >3%, and 4 (57.1%) of them experienced NAS regression. No significant effect of weight reduction on the progression of fibrosis was observed. The short‐term lifestyle modification program significantly decreased liver enzymes and metabolic parameters in NASH patients. A more precise or intensive program may be needed for fibrosis improvement. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Third vaccine boosters and anti‐S‐IgG levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma.

Author

Wang, Chih‐Wen, Huang, Chung‐Feng, Jang, Tyng‐Yuan, Yeh, Ming‐Lun, Liang, Po‐Cheng, Wei, Yu‐Ju, Hsu, Po‐Yao, Huang, Ching‐I., Hsieh, Ming‐Yen, Lin, Yi‐Hung, Huang, Jee‐Fu, Dai, Chia‐Yen, Chuang, Wan‐Long, and Yu, Ming‐Lung

Subjects
SARS-CoV-2, BOOSTER vaccines, COVID-19, HEPATOCELLULAR carcinoma, IMMUNE response
Abstract

The immune response of patients with chronic liver disease tends to be lower after receiving their second coronavirus disease 2019 (COVID‐19) vaccine dose, but the effect of a third vaccine dose on their immune response is currently unknown. We recruited 722 patients without previous severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection from three hospitals. The patients received homologous (MMM) and heterologous (AZAZBNT, AZAZM) boosters, where AZ, BNT, and M denoted the AZD1222, BNT162b2, and mRNA‐1273 vaccines, respectively. Serum IgG spike antibody levels were measured at a mean 1.5 ± 0.7 (visit 1) and 5.0 ± 0.5 (visit 2) months after the third vaccine booster. A threshold of 4160 AU/mL was considered significant antibody activity. In both visits, the patients who received the MMM booster had higher anti‐S‐IgG levels than those who received the AZAZBNT and AZAZM boosters. Patients with active hepatocellular carcinoma (HCC) had lower anti‐S‐IgG levels than the control group (761.6 vs. 1498.2 BAU/mL; p = 0.019) at visit 1. The anti‐S‐IgG levels decreased significantly at visit 2. The patients with significant antibody activity had a lower rate of liver cirrhosis with decompensation (0.7% decompensation vs. 8.0% non‐decompensation and 91.3% non‐liver cirrhosis, p = 0.015), and active HCC (1.5% active HCC vs. 3.7% non‐active HCC and 94.7% non‐HCC, p < 0.001). Receiving the MMM booster regimen (OR = 10.67, 95% CI 5.20–21.91, p < 0.001) increased the odds of having significant antibody activity compared with the AZAZBNT booster regimen. Patients with active HCC had a reduced immune response to the third COVID‐19 vaccine booster. These findings underscore the importance of booster vaccinations, especially in immunocompromised patients, with superior efficacy observed with the homologous mRNA‐1273 regimen. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis.

Author

Huang, Chung‐Feng, Liang, Po‐Cheng, Wang, Chih‐Wen, Jang, Tyng‐Yuan, Hsu, Po‐Yao, Tsai, Pei‐Chien, Wei, Yu‐Ju, Yeh, Ming‐Lun, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Huang, Chao‐Kuan, Dai, Chia‐Yen, Huang, Jee‐Fu, Chuang, Wan‐Long, and Yu, Ming‐Lung

Subjects
HEPATIC fibrosis, VIRAL hepatitis, FATTY liver, RECEIVER operating characteristic curves, LIVER diseases
Abstract

The accuracy of noninvasive seromarkers in predicting liver fibrosis in metabolic dysfunction‐associated fatty liver disease (MAFLD) patients with or without viral hepatitis is elusive. The AST to platelet ratio index (APRI), fibrosis‐4 index (FIB‐4), and NAFLD fibrosis score (NFS) were assessed in 871 MAFLD patients who received elastography in a viral hepatitis‐endemic area. The area under the receiver operating characteristic (AUROC) curve increased substantially with increasing fibrotic stage across the three biomarkers. APRI (AUROC range 0.73–0.80) and FIB‐4 (AUROC range 0.66–0.82) performed better than NFS (AUROC range 0.63–0.75). When patients were divided into viral and non‐viral MAFLD groups, a better AUROC of APRI (range 0.76–0.80) and FIB‐4 (range 0.68–0.78) than NFS (range 0.62–70) existed only in viral MALFD but not in non‐viral MAFLD. Regarding the NFS, the AUROC was higher in non‐viral MAFLD (range 0.69–0.86) and outperformed viral MAFLD at all fibrotic stages. The accuracy in predicting liver fibrosis increased with the advancement of liver disease for the three biomarkers. NFS exerted better diagnostic accuracy in non‐viral than in viral MAFLD patients across different fibrotic stages. The best accuracy was 91.1% using the cutoff value of −9.98 for the NFS in predicting liver cirrhosis in non‐viral MAFLD patients. The APRI and FIB‐4 performed better than the NFS in predicting liver fibrosis in MAFLD as a whole. The suboptimal performance and accuracy of the NFS existed only in viral MAFLD patients. Caution should be taken when assessing the NFS in MAFLD patients with viral hepatitis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan

Author

Lu, Ming-Ying, Chen, Chun-Ting, Shih, Yu-Lueng, Tsai, Pei-Chien, Hsieh, Meng-Hsuan, Huang, Chung-Feng, Yeh, Ming-Lun, Huang, Ching-I, Wang, Shu-Chi, Tsai, Yi-Shan, Ko, Yu-Min, Lin, Ching-Chih, Chen, Kuan-Yu, Wei, Yu-Ju, Hsu, Po-Yao, Hsu, Cheng-Ting, Jang, Tyng-Yuan, Liu, Ta-Wei, Liang, Po-Cheng, Hsieh, Ming-Yen, Lin, Zu-Yau, Chen, Shinn-Cherng, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Chang, Wen-Yu

Published
2021
Full Text
View/download PDF

38. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

Author

Huang, Chung-Feng, Kuo, Hsing-Tao, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Chen, Chi-Yi, Tseng, Kuo-Chih, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

39. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues

Author

Jang, Tyng-Yuan, Wei, Yu-Ju, Liu, Ta-Wei, Yeh, Ming-Lun, Liu, Shu-Fen, Hsu, Cheng-Ting, Hsu, Po-Yao, Lin, Yi-Hung, Liang, Po-Cheng, Hsieh, Meng-Hsuan, Ko, Yu-Min, Tsai, Yi-Shan, Chen, Kuan-Yu, Lin, Ching-Chih, Tsai, Pei-Chien, Wang, Shu-Chi, Huang, Ching-I., Lin, Zu-Yau, Chen, Shinn-Cherng, Chuang, Wan-Long, Huang, Jee-Fu, Dai, Chia-Yen, Huang, Chung-Feng, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

41. Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response.

Author

Park, Jung Eun, Nguyen, Vy H., Tsai, Pei‐Chien, Toyoda, Hidenori, Leong, Jennifer, Guy, Jennifer E., Yeh, Ming‐Lun, Huang, Chung‐Feng, Yasuda, Satoshi, Abe, Hiroshi, Hsu, Yao‐Chun, Tseng, Cheng‐Hao, Liu, Joanne, Chen, Yao‐Li, Lin, Ping‐Yi, Jun, Dae Won, Yoshimaru, Yoko, Ogawa, Eiichi, Ishigami, Masatoshi, and Enomoto, Masaru

Subjects
HEPATITIS C virus, HEPATOCELLULAR carcinoma, RACIAL inequality, BLACK people, ASIANS, LIVER cancer
Abstract

Summary: Background: Racial and ethnic disparities exist for hepatitis C virus (HCV) treatment and hepatocellular carcinoma (HCC) survival. Aim: To evaluate the impact of HCV treatment on such disparities. Methods: In a retrospective cohort study, we analysed 6069 patients with HCV‐related HCC (54.2% Asian, 30.1% White, 8.5% Black, and 7.3% Hispanic) from centres in the United States and Asia. Results: The mean age was 61, 60, 59 and 68, respectively, for White, Black, Hispanic and Asian patients. Black patients were most likely to have Barcelona Clinic Liver Cancer stage D, vascular invasion and distant metastasis (23% vs. 5%–15%, 20% vs. 10%–17% and 10% vs. 5%–7%, respectively; all p < 0.0001). Treatment rate with direct‐acting antiviral agents (DAA) was 35.9% for Asian, 34.9% for White, 30.3% for Hispanic (30.3%), and 18.7% for Black patients (p < 0.0001). Among those untreated or without sustained virologic response (SVR), 10‐year survival rates were 35.4, 27.5, 19.3 and 14.0, respectively, for Asian, Hispanic, White and Black patients (p < 0.0001). There were no statistically significant differences among those with SVR (p = 0.44). On multivariable analysis adjusted for relevant confounders, there was no statistically significant association between survival and being Hispanic (aHR: 0.68, p = 0.26) or Black (aHR: 1.18, p = 0.60) versus White. There was a significant association between being Asian American and survival (aHR: 0.24, p = 0.001; non‐U.S. Asian: aHR: 0.66, p = 0.05), and for SVR (aHR: 0.30, p < 0.0001). Conclusion: DAA treatment rates were suboptimal. Racial and ethnic disparities resolved with HCV cure. Early diagnosis and improved access to HCV treatment is needed for all patients with HCV infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma.

Author

Huang, Daniel Q., Hoang, Joseph K., Kamal, Rubayet, Tsai, Pei-Chien, Toyoda, Hidenori, Yeh, Ming-Lun, Yasuda, Satoshi, Leong, Jennifer, Maeda, Mayumi, Huang, Chung-Feng, Won Jun, Dae, Ishigami, Masatoshi, Tanaka, Yasuhito, Uojima, Haruki, Ogawa, Eiichi, Abe, Hiroshi, Hsu, Yao-Chun, Tseng, Cheng-Hao, Alsudaney, Manaf, and Yang, Ju Dong

Published
2024
Full Text
View/download PDF

43. Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease.

Author

Jang, Tyng‐Yuan, Ho, Chi‐Chang, Liang, Po‐Cheng, Wu, Chih‐Da, Wei, Yu‐Ju, Tsai, Pei‐Chien, Hsu, Po‐Yao, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Hsieh, Meng‐Hsuan, Wang, Chih‐Wen, Yang, Jeng‐Fu, Yeh, Ming‐Lun, Huang, Chung‐Feng, Chuang, Wan‐Long, Huang, Jee‐Fu, Cheng, Ya‐Yun, Dai, Chia‐Yen, Chen, Pau‐Chung, and Yu, Ming‐Lung

Subjects
AIR pollution, HEPATIC fibrosis, CHRONICALLY ill, AIR pollutants, CHRONIC hepatitis B
Abstract

We aimed to investigate the association between air pollution and advanced fibrosis among patients with metabolic associated fatty liver disease (MAFLD) and chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A total of 1376 participants who were seropositive for HBV surface antigen (HBsAg) or antibodies to HCV (anti‐HCV) or had abnormal liver function in a community screening program from 2019 to 2021 were enrolled for the assessment of liver fibrosis using transient elastography. Daily estimates of air pollutants (particulate matter ≤2.5 μm in diameter [PM2.5], nitrogen dioxide [NO2], ozone [O3] and benzene) were aggregated into mean estimates for the previous year based on the date of enrolment. Of the 1376 participants, 767 (52.8%) and 187 (13.6) had MAFLD and advanced fibrosis, respectively. A logistic regression analysis revealed that the factors associated with advanced liver fibrosis were HCV viremia (odds ratio [OR], 3.13; 95% confidence interval [CI], 2.05–4.77; p < 0.001), smoking (OR, 1.79; 95% CI, 1.16–2.74; p = 0.01), age (OR, 1.04; 95% CI, 1.02–1.05; p < 0.001) and PM2.5 (OR, 1.10; 95% CI, 1.05–1.16; p < 0.001). Linear regression analysis revealed that LSM was independently correlated with PM2.5 (β: 0.134; 95% CI: 0.025, 0.243; p = 0.02). There was a dose‐dependent relationship between different fibrotic stages and the PM2.5 level (the PM2.5 level in patients with fibrotic stages 0, 1–2 and 3–4: 27.9, 28.4, and 29.3 μg/m3, respectively; trend p < 0.001). Exposure to PM2.5, as well as HBV and HCV infections, is associated with advanced liver fibrosis in patients with MAFLD. There was a dose‐dependent correlation between PM2.5 levels and the severity of hepatic fibrosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study.

Author

Ogawa, Eiichi, Jun, Dae Won, Toyoda, Hidenori, Hsu, Yao‐Chun, Yoon, Eileen L., Ahn, Sang Bong, Yeh, Ming‐Lun, Do, Son, Trinh, Huy N., Takahashi, Hirokazu, Enomoto, Masaru, Kawada, Norifumi, Yasuda, Satoshi, Tseng, Cheng‐Hao, Kawashima, Keigo, Lee, Han Ah, Inoue, Kaori, Haga, Hiroaki, Do, Ai‐Thien, and Maeda, Mayumi

Subjects
CHRONIC hepatitis B, BONE density, SPINE, TENOFOVIR, ALANINE aminotransferase, GLOMERULAR filtration rate
Abstract

Summary: Background: Data on patients switched to tenofovir alafenamide (TAF) from nucleos(t)ide analogues (NUCs) other than tenofovir disoproxil fumarate are limited. Aims: To assess the treatment and renal/bone safety outcomes following the switch to TAF. Methods: We prospectively enrolled adult patients with chronic hepatitis B (CHB) who switched from any NUC to TAF at 14 centres in Japan, Korea, Taiwan and the U.S. Study outcomes were viral suppression (VR; HBV DNA < 20 IU/mL), biochemical response (BR; alanine aminotransferase normalisation), and changes in estimated glomerular filtration rate (eGFR) and T‐scores (L‐spine) by bone absorptiometry by 24 months after switch to TAF. Results: We enrolled 270 eligible patients. Mean age was 58.1; 58.2% were male; 12.2% had cirrhosis and 73.3% previously received entecavir monotherapy. VR rate increased significantly from 95.2% to 98.8% by 24 months after the switch to TAF (p = 0.014). Between the switch and 24 months later, the mean spine T‐score improved significantly from −1.43 ± 1.36 to −1.17 ± 1.38 (p < 0.0001), while there was no significant change in mean eGFR (88.4 ± 16.9–89.5 ± 16.3 mL/min/1.73 m2, p = 0.13). On multivariable analysis adjusted for age, sex, baseline spine T‐score and prior TDF or adefovir dipivoxil use, male sex was significantly associated with lower risk of worsening spine T‐score (odds ratio: 0.29, p = 0.020), while age was significantly associated with a higher risk of worsening chronic kidney disease stage (OR: 1.07, p = 0.019). Conclusions: At 24 months after the switch to TAF, VR rates and spine bone density improved significantly while renal function remained stable. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Patient‐centered and integrated outreach care for chronic hepatitis C patients with serious mental illness in Taiwan.

Author

Huang, Chung‐Feng, Jang, Tyng‐Yuan, Yu, Shun‐Chieh, Huang, Shin‐Chung, Ho, Shao‐Lun, Yeh, Ming‐Lun, Wang, Chih‐Wen, Liang, Po‐Cheng, Wei, Yu‐Ju, Hsu, Po‐Yao, Huang, Ching‐I, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Yu, Sung‐Lin, Wu, Pey‐Fang, Chen, Yu‐Han, Chien, Shin‐Chi, Huang, Jee‐Fu, Dai, Chia‐Yen, and Chuang, Wan‐Long

Subjects
PEOPLE with mental illness, CHRONIC hepatitis C, HEPATITIS C, HEPATITIS C virus, DELAYED diagnosis, DISEASE risk factors, PSYCHIATRIC nursing
Abstract

Patients with serious mental illness have a higher risk of hepatitis C virus (HCV) infection but suboptimal HCV care. The current study aimed to facilitate HCV treatment uptake by implementing an integrated outreach care model. Multidisciplinary outreach screening followed by HCV reflex testing and onsite treatment for schizophrenia patients was accomplished through the coordination of nongovernmental organizations, remote specialists, and local care providers. The objective was microelimination effectiveness, defined as the multiplication of the rates of anti‐HCV antibodies screening, accurate HCV RNA diagnosis, treatment allocation, treatment completion, and sustained virological response (SVR12; no detectable HCV RNA throughout 12 weeks in the post‐treatment follow‐up period). A total of 1478 of the 2300 (64.3%) psychiatric patients received HCV mass screening. Seventy‐three (4.9%) individuals were seropositive for anti‐HCV antibodies. Of the 73 anti‐HCV seropositive patients, all (100%) received HCV reflex testing, and 29 (37.7%) patients had HCV viremia. Eight patients (34.8%) had advanced liver disease, including 3 with liver cirrhosis and 2 with newly diagnosed hepatocellular carcinoma. Twenty‐three of the 24 (95.8%) patients who stayed in the healthcare system received and completed 8 weeks of glecaprevir/pibrentasvir treatment and post‐treatment follow‐up without significant DDIs or adverse events. The SVR12 rate was 100%. The microelimination effectiveness in the current study was 61.6%. Individuals with serious mental illness are underserved and suffer from diagnostic delays. This patient‐centered and integrated outreach program facilitated HCV care in this marginalized population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area.

Author

Huang, Chung‐Feng, Liang, Po‐Cheng, Tsai, Pei‐Chien, Wei, Yu‐Ju, Huang, Ching‐I, Wang, Chih‐Wen, Jang, Tyng‐Yuan, Yeh, Ming‐Lun, Hsu, Po‐Yao, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Dai, Chia‐Yen, Chuang, Wan‐Long, Huang, Jee‐Fu, and Yu, Ming‐Lung

Subjects
FATTY liver, VIRAL hepatitis, LIVER diseases, VIRUS diseases, HEPATITIS C virus
Abstract

Background and Aim: The prevalence of metabolic dysfunction‐associated fatty liver disease (MAFLD) and its interplay with hepatitis B virus (HBV) and hepatitis C virus (HCV) in terms of liver disease severity is elusive. Methods: A mass surveillance program was conducted in a viral hepatitis endemic area. The objective was to identify MAFLD/non‐MAFLD subjects with advanced liver disease. Results: Two thousand two hundred and forty‐two (41.7%) of the 5378 subjects were identified as having MAFLD, and 375 (7.0%) had advanced liver disease. The proportions of anti‐HCV and HBsAg seropositivity were 19.3% and 9.7%, respectively. The proportions of advanced fibrosis in subjects with non‐viral hepatitis (NBNC), HBV and HCV infection were 2.8%, 5.7% and 23.4%, respectively. Subjects with MAFLD had a significantly higher proportion of advanced fibrosis (8.7% vs 5.7%, P < 0.001). Factors associated with advanced fibrosis included age (odds ratio [OR]/95% confidence interval [CI]: 4.8/3.7–6.0, P < 0.001), male sex (OR/CI: 1.3/1.0–1.7, P = 0.019), anti‐HCV seropositivity (OR/CI: 5.9/4.6–7.5, P = 0.019), MAFLD‐lean metabolic dysregulation (MS) (OR/CI: 2.6/1.3–5.2, P = 0.005; compared with the non‐MAFLD group) and MAFLD‐diabetes (OR/CI: 1.5/1.1–2.1, P = 0.008; compared with the non‐MAFLD group). MAFLD did not aggravate liver disease severity in patients with viral hepatitis. However, among NBNC subjects, factors associated with advanced liver disease included MAFLD‐lean MS group (OR/CI: 9.1/2.4–34.6, P = 0.001; compared with non‐MAFLD group) and MAFLD‐DM group (OR/CI: 2.0/1.2–3.2, P = 0.004; compared with non‐MAFLD group). Conclusions: MAFLD patients with diabetes and metabolic dysregulation had a higher risk of advanced liver disease. The effect was more significant in non‐viral hepatitis subjects in a community level. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study.

Author

Huang, Chung-Feng, Dai, Chia-Yen, Wang, Chih-Wen, Liang, Po-Cheng, Wei, Yu-Ju, Tsai, Pei-Chien, Jang, Tyng-Yuan, Hsu, Po-Yao, Lee, Jia-Jung, Niu, Sheng-Wen, Huang, Jiun-Chi, Yeh, Ming-Lun, Huang, Ching-I, Hsieh, Ming-Yen, Lin, Yi-Hung, Chen, Szu-Chia, Chiu, Yi-Wen, Huang, Jee-Fu, Chang, Jer-Ming, and Hwang, Shang-Jyh

Subjects
HEPATITIS C virus, PATIENT experience, COHORT analysis, HEMODIALYSIS, LONGITUDINAL method
Abstract

Background The World Health Organization has established interim guidance for hepatitis C virus (HCV) elimination. We aimed to prove the concept of "treatment as prevention" by conducting a prospective HCV elimination program for hemodialysis (HD) patients. Methods A universal HCV screen was launched in 22 HD centers in 2019. HCV-viremic patients were linked to care with direct-acting antivirals (DAAs). The second screen was performed in 2021 to evaluate the effect of link-to-care in lowering the prevalence of HCV viremia and the incidence of HCV new/re-infections. Results Of 2336 patients enrolled in the first screening in 2019, 320 (13.7%) were seropositive for anti-HCV and 181 (7.7%) were HCV-viremic. Of 152 patients successfully linked to treat with DAA, 140 (92.1%) patients achieved a sustained virological response. Of them, 1733 patients participated in the second surveillance. Five anti-HCV-negative patients experienced anti-HCV seroconversion. Of 119 DAA-cured patients and 102 spontaneous HCV clearance patients, none had HCV reinfection. The annual incidence of HCV new infection was 0.1%. Sixty-one of the 620 (9.8%) newly enrolled patients were anti-HCV-seropositive in the second survey. The overall HCV-viremic rate decreased from 7.7% in 2019 to 0.6% (15/2353) in 2021. At the institutional level, 45.5% (10/22) eradicated HCV and 82% (18/22) of HD units had no HCV new infections or reinfections. Conclusions The link-to-care project proved the concept of "treatment as prevention" by which HCV microelimination helps to prevent reinfection and new infections in the HD population. Trial registration: ClinicalTrials.gov identifier: NCT03803410 and NCT03891550. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results